CRISPR and Gene Editing: A New Frontier in Healthcare
DOI:
https://doi.org/10.55938/wlp.v1i1.85Keywords:
human genomics, CRISPR/Cas, genome editing, precision medicineAbstract
The potential for significant advancements in disease management is highlighted by this review, which looks at the application of CRISPR gene editing for treating allergies, particularly those related to allergens. It also evaluates the benefits and limitations of this technique in relation to existing treatment options. When it comes to treating medical illnesses like cancer, hepatitis B, cardiovascular disorders, and excessive cholesterol, CRISPR-Cas9 technology provides a rapid, precise, and effective way to manipulate DNA. The issue of reducing mismatches between sgRNA and genomic DNA caused by Cas9 is addressed. A wide range of genome-editing methods are discussed in this chapter, including as CRISPR/Cas9 systems, TALENs, and vector-based transfection. An overview of the prospective applications of gene modification techniques for the treatment of cardiovascular, hematological, neurological, viral, and cancer illnesses is also included, along with translational advances in ex vivo and in vivo studies. The roles of gene treatments, artificial intelligence (AI), and genetic testing in educational and medical settings are reviewed in this article, which also highlights moral concerns and emphasizes the necessity to develop novel legislative frameworks for their assessment and supervision. In order to emphasize the importance of further advancement, it also addresses situations in which these technologies exceed current ethical standards. The article discusses the developments in gene therapy, especially CRISPR-Cas9 and CAR-T cell therapy, as well as the constraints and critical thinking that must be addressed for oncology to proceed. It highlights the necessity of a multidisciplinary strategy, ethical supervision, and efforts to make things more affordable and accessible.
References
Baldassarre, D., Piazza, O., & McConnell, P. (2023). Emerging ethical challenges in healthcare in the 21st century. Anaesthesia & Intensive Care Medicine.
Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G., & Nowak, K. J. (2019). Optimizing precision medicine for public health. Frontiers in public health, 7, 42.
Dwivedi, S., Purohit, P., Vasudeva, A., Kumar, M., Agrawal, R., Sheikh, N. A., ... & Misra, S. (2022). Gene therapy and gene editing in healthcare. In Biotechnology in Healthcare (pp. 147-175). Academic Press.
Moumaris, M. (2023). Revolutionizing Malaria Research: CRISPR unveils New Frontiers. J, Biotechnology and Bioprocessing, 4(5), 2766-2314.
Ding, R., Long, J., Yuan, M., Jin, Y., Yang, H., Chen, M., ... & Duan, G. (2021). CRISPR/Cas system: a potential technology for the prevention and control of COVID-19 and emerging infectious diseases. Frontiers in cellular and infection microbiology, 11, 639108.
Ruikar, S. S., Masurkar, S. A., & Ghatage, A. A. (2024). Gene Therapy Innovations: A New Frontier in Cancer Biology Treatment. NATURALISTA CAMPANO, 28(1), 29-35.
Niazi, S. K. (2023). In Vivo Gene Editing: A Healthcare Revolution in the Making.
Chawla, S., & Tyagi, K. (2024). The CRISPR-Cas technology: trends in healthcare. In CRISPR-Cas System in Translational Biotechnology (pp. 109-130). Academic Press.
Qiu, M., & Li, P. (2021). CRISPR/Cas-based diagnostics and gene therapy. BIO Integration, 2(3), 121-129.
Tavakoli, K., Pour-Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021). Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences. BioTech, 10(3), 14.
Srivastava, A., Chauhan, S., & Ahuja, V. (2023). Recent advances in CRISPR/Cas9-assisted gene therapy. Karbala International Journal of Modern Science, 9(4), 6.
Shademan, B., Nourazarian, A., Hajazimian, S., Isazadeh, A., Biray Avci, C., & Oskouee, M. A. (2022). CRISPR technology in gene-editing-based detection and treatment of SARS-CoV-2. Frontiers in molecular biosciences, 8, 772788.
Brackett, N. F., Pomés, A., & Chapman, M. D. (2022). New frontiers: precise editing of allergen genes using CRISPR. Frontiers in allergy, 2, 821107.
Saeed, S., Khan, S. U., Khan, W. U., Abdel-Maksoud, M. A., Mubarak, A. S., Aufy, M., ... & Saleem, M. H. (2023). Genome editing technology: a new frontier for the treatment and prevention of cardiovascular diseases. Current Problems in Cardiology, 48(7), 101692.
Zaib, S., Saleem, M. A., & Khan, I. (2022). CRISPR-Cas9 genome engineering: trends in medicine and health. Mini reviews in medicinal chemistry, 22(3), 410-421.
Guo, M., Chen, H., Dong, S., Zhang, Z., & Luo, H. (2022). CRISPR-Cas gene editing technology and its application prospect in medicinal plants. Chinese medicine, 17(1), 33.
Hernández-Juárez, J., Rodríguez-Uribe, G., & Borooah, S. (2021). Toward the treatment of inherited diseases of the retina using CRISPR-based gene editing. Frontiers in Medicine, 8, 698521.
Lewis, B. S. (2024). First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA.
Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. D. R., & Krishnan, N. R. (2023). Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions. Frontiers in Bioengineering and Biotechnology, 11.
Wagner, D. L., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R. (2022). sustainable clinical development of CAR-T cells–switching from viral transduction towards CRISPR-Cas gene editing. Frontiers in immunology, 13, 865424.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Wisdom Leaf Press
This work is licensed under a Creative Commons Attribution 4.0 International License.